TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04752826: Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 as a Single Agent and in Combination With Pembrolizumab (MK-3475-D20) in Subjects With Advanced Malignancies

Sponsor: BioInvent International AB · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$628,320

Rescue Site Savings

+$431,970

Unlock Full NCT04752826 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04752826 Rescue Dossier →